AbbVie Inc. (0QCV.L)
LSE - LSE Delayed price. Currency in EUR
Add to watchlist
89.63+9.15 (+11.37%)
As of 11:39AM GMT. Market open.
| Previous close | 80.48 |
| Open | 104.39 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 104.39 - 104.39 |
| 52-week range | 104.39 - 104.39 |
| Volume | 400 |
| Avg. volume | N/A |
| Market cap | 133.665B |
| Beta (5Y monthly) | 0.83 |
| PE ratio (TTM) | 24.17 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet
COPENHAGEN, Denmark & NORTH CHICAGO, Ill., September 09, 2021--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced The Lancet published the results of the dose escalation part of the phase 1/2 EPCORE™ NHL-1 first-in-human (FIH) dose escalation and cohort expansion clinical trial evaluating safety and preliminary efficacy of the investigational therapy epcoritamab (DuoBody®-CD3xCD20) in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL). The full manuscript is a
© 2021 Verizon Media. All rights reserved.
